Organization
GE Healthcare
11 clinical trials
1 abstract
Clinical trial
A Phase 4, Open-Label, Non-randomized, Multicenter Study to Evaluate Safety and Efficacy of Intravenous Administration of OPTISON™ for Contrast- Enhanced Echocardiography in Pediatric PatientsStatus: Completed, Estimated PCD: 2023-03-30
Clinical trial
An Open-label Multicenter Phase 2 Dose-evaluation Study of Altropane (123I) Injection for Striatal Dopamine Transporter Visualization Using SPECT Brain ImagingStatus: Recruiting, Estimated PCD: 2024-03-29
Clinical trial
A Phase 1 Study to Assess the Safety, Radiation Dosimetry and Biodistribution, and Basic Pharmacokinetics of [18F]GEH121224 and Determine the Optimal Timing of Imaging in Patients With Locally Advanced or Metastatic Breast Cancer.Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 3, Open-Label, Multicentre Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery DiseaseStatus: Completed, Estimated PCD: 2022-05-05
Clinical trial
A Phase 1a/1b, Multi-Centre, Open-Label, Dose-Escalation and Dose-Expansion Study in Patients With Solid Tumour Malignancies to Evaluate GEH200520 Injection / GEH200521 (18F) Injection Safety and Tolerability, PET Imaging, Pharmacokinetics, and Changes in Imaging After TreatmentStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 1 Single Centre, Single Ascending Dose Safety Study of GEH200486 in Healthy VolunteersStatus: Completed, Estimated PCD: 2022-11-29
Clinical trial
A Phase 1, Non-randomised, Noncomparative, Open-label Study to Assess the Safety, Biodistribution, and Internal Radiation Dosimetry of a Single Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy VolunteersStatus: Completed, Estimated PCD: 2021-09-04
Clinical trial
An Open-label, Single-dose, Safety and Pharmacokinetic Study of Regadenoson in Pediatric PatientsStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy ControlsStatus: Completed, Estimated PCD: 2021-12-20
Clinical trial
A Descriptive, Comparative, Randomized, Crossover Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion Imaging Quality Using High Performance Liquid Chromatography (HPLC) and Solid Phase Extraction (SPE) Manufacturing ProcessesStatus: Completed, Estimated PCD: 2022-05-26
Clinical trial
A Phase 1, Single-Center, Open-Label, Single-Arm, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety and Tolerability, Immunogenicity, Pharmacokinetics, Dosimetry and Biodistribution Following GEH200521 (18F) Injection Co-Administered With GEH200520 Injection in Healthy VolunteersStatus: Not yet recruiting, Estimated PCD: 2025-05-01
Abstract
Potential improvement in the diagnostic accuracy in detecting the estrogen receptor status in metastatic and recurrent breast cancer using 18F-FES PET/CT in the US.Org: GE Healthcare, Marlborough, Certara Germany GmbH, Lörrach, London Regional Cancer Center,